Disclosed are a novel class of anti-androgenic compounds including saturated and unsaturated fatty acids, their derivatives, and synthetic analogs, according to the following formula: wherein R.sub.1 and R.sub.2 are each either hydrogen or a halogen; wherein a and c are integers from 0-9; wherein b is an integer from 1-6, provided that Also disclose are methods of synthesis of these compounds, and their use in treating disorders associated with androgenic activities. Also disclosed is the use of...

The invention relates generally to compositions of and methods for obtaining ubiquitous, nuclear receptor (UR) polypeptides. The invention also relates to polynucleotides encoding UR polypeptides, recombinant host cells and vectors containing UR-encoding polynucleotide sequences, and recombinant UR polypeptides. By way of example, the invention discloses the cloning and functional expression of at least two different UR polypeptides. The invention also includes methods for using the isolated, re...

Disclosed are DNA sequences encoding DNA binding polypeptides including androgen receptor (AR) and TR2 polypeptides. Illustratively, human and rat AR-cDNA have 79 kD and 98 kD polypeptide expression products which are immunoprecipitable by human auto-immune anti-androgen receptor antibodies and are capable of binding androgens specifically and with high affinity. Also disclosed are antibodies and immunological methods and materials for detection of androgen receptor and TR2 polypeptides and hybr...

Disclosed are a novel class of antiandrogenic compounds including saturated and unsaturated fatty acids, catechin gallates, their derivatives, and synthetic analogs, their method of synthesis, and their use in treating disorders associated with androgenic activities. Also disclosed is the use of known compounds not previously known for their antiandrogenic activity in treating disorders related to androgenic activities and cancers.

Compounds that inhibit 5-alpha-reductase are provided. The compounds are used to treat prostate cancer, breast cancer, obesity, skin disorders and baldness.

Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5.alpha.-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5....

Steroid derivatives of this invention interact with nuclear liver X receptor (LXR) and ubiquitous receptor (UR) and can be used to treat a variety of LXR- or UR-mediated disorders.

A compound of formula (I): ##STR00001## Each of R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.4', R.sub.5, R.sub.6, R.sub.7, R.sub.11, R.sub.12, R.sub.15, R.sub.16, and R.sub.17, independently, is hydrogen, halo, alkyl, haloalkyl, hydroxy, amino, carboxyl, oxo, sulfonic acid, or alkyl that is optionally inserted with --NH--, --N(alkyl)--, --O--, --S--, --SO--, --SO.sub.2--, --O--SO.sub.2--, --SO.sub.2--O--, --SO.sub.3--O--, --CO--, --CO--O--, --O--CO--, --CO--NR'--, or --NR'--CO--; or R.sub.3 and R....

A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): ##STR00001## Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver X alpha is indicated, such as in, for example, treating a high cholesterol disease.

Disclosed are novel classes of anti-androgen including dihydrophenanthrene derivatives, their method of synthesis and their use in treating disorders associated with excessive androgenic activities.